Roger Williams Medical Center
23
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
47.8%
11 terminated/withdrawn out of 23 trials
42.1%
-44.4% vs industry average
0%
0 trials in Phase 3/4
63%
5 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (23)
Assessment of the Effectiveness of Chemotherapy Teaching: BrUOG 258
Role: collaborator
Decitabine, Cytarabine, GCSF for Refractory AML/MDS
Role: collaborator
CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer
Role: lead
Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma
Role: lead
Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer
Role: collaborator
Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial
Role: collaborator
RAD001, Cisplatin and Concurrent Radiation for Locally Advanced, Inoperable Head and Neck Cancer
Role: collaborator
Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen
Role: collaborator
CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases
Role: lead
Study of the Effectiveness of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Fibrin to Treat Chronic Wounds
Role: lead
Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
Role: lead
Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer
Role: lead
Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
Role: lead
Trial of Second Generation Designer T Cells in Colorectal Carcinoma
Role: lead
Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas
Role: lead
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer
Role: lead
Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors
Role: lead
Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer
Role: lead
Bioengineered Skin and Wound Healing
Role: lead
CEA-Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti-CEA Designer T Cells
Role: lead